Global Pharmacogenomics Partnering Terms and Agreements 2010-2016 Entered into by the World's Leading Healthcare Companies

Mar 17, 2016, 13:10 ET from Research and Markets

DUBLIN, March 17, 2016 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2016" report to their offering.

The Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the pharmacogenomic partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Pharmacogenomics agreements announced in the healthcare sectors. Pharmacogenomics focusses on the influence of genetic variation on drug response in patients by correlating gene expression or single nucleotide polymorphisms with a drug's efficacy or toxicity.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

In Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2016, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Pharmacogenomics dealmaking

Chapter 3 - Leading Pharmacogenomics deals

Chapter 4 - Most active Pharmacogenomics dealmakers

Chapter 5 - Pharmacogenomics contracts dealmaking directory

Chapter 6 - Pharmacogenomics dealmaking by technology type

Chapter 7 - Partnering resource center

For more information visit

Media Contact:

Research and Markets

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716


SOURCE Research and Markets